IFNB1 and myeloid sarcoma: The seminal discovery of the therapeutic effect of IFN-β on relapsing-remitting Multiple Sclerosis [MS; (20, 21)] has led to the clinical use of IFN-β as the first disease-modifying drug approved for relapsing-remitting MS.